480 related articles for article (PubMed ID: 29684191)
1. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Philbert BT; Torp-Pedersen C; Riahi S; Jøns C
Europace; 2018 Sep; 20(FI2):f217-f224. PubMed ID: 29684191
[TBL] [Abstract][Full Text] [Related]
2. The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Petersen HH; Torp-Pedersen C; Riahi S; Jøns C
Europace; 2018 Feb; 20(2):301-307. PubMed ID: 28339659
[TBL] [Abstract][Full Text] [Related]
3. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Ruwald MH; Ruwald AC; Jons C; Alexis J; McNitt S; Zareba W; Moss AJ
J Am Coll Cardiol; 2013 Apr; 61(14):1518-26. PubMed ID: 23500269
[TBL] [Abstract][Full Text] [Related]
4. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
[TBL] [Abstract][Full Text] [Related]
5. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
[TBL] [Abstract][Full Text] [Related]
6. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
7. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
[TBL] [Abstract][Full Text] [Related]
8. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
[TBL] [Abstract][Full Text] [Related]
9. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
Ruwald MH; Abu-Zeitone A; Jons C; Ruwald AC; McNitt S; Kutyifa V; Zareba W; Moss AJ
J Am Coll Cardiol; 2013 Oct; 62(15):1343-50. PubMed ID: 23770172
[TBL] [Abstract][Full Text] [Related]
10. Association of device detected atrial and ventricular tachyarrhythmia with adverse events in patients with an implantable cardioverter-defibrillator.
Abbas H; Younis A; Goldenberg I; McNitt S; Aktas MK; Tabaja C; Ojo A
J Cardiovasc Electrophysiol; 2024 Jun; 35(6):1203-1211. PubMed ID: 38606650
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
13. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention.
Streitner F; Kuschyk J; Dietrich C; Mahl E; Streitner I; Doesch C; Veltmann C; Schimpf R; Wolpert C; Borggrefe M
Clin Cardiol; 2011 Oct; 34(10):604-9. PubMed ID: 21887690
[TBL] [Abstract][Full Text] [Related]
15. A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
Ayan M; Habash F; Alqam B; Gheith Z; Cross M; Vallurupalli S; Paydak H
Clin Cardiol; 2019 Feb; 42(2):299-304. PubMed ID: 30592068
[TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation increases the risk of recurrent ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients.
Rusnak J; Behnes M; Reiser L; Schupp T; Bollow A; Reichelt T; Borggrefe M; Ellguth D; Engelke N; El-Battrawy I; Ansari U; Barre M; Weidner K; Müller J; Barth C; Meininghaus DG; Akin M; Bertsch T; Taton G; Akin I
Arch Cardiovasc Dis; 2021; 114(6-7):443-454. PubMed ID: 33967015
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study.
Christensen AM; Bjerre J; Schou M; Jons C; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Ruwald AC
Europace; 2019 Mar; 21(3):465-474. PubMed ID: 30535192
[TBL] [Abstract][Full Text] [Related]
18. Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction: A MADIT-CRT Substudy (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy).
Biering-Sørensen T; Knappe D; Pouleur AC; Claggett B; Wang PJ; Moss AJ; Solomon SD; Kutyifa V
Circ Cardiovasc Imaging; 2017 Jan; 10(1):. PubMed ID: 28003221
[TBL] [Abstract][Full Text] [Related]
19. Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients.
Diamond A; Goldenberg I; Younis A; Goldenberg I; Sampath R; Kutyifa V; Chen AY; McNitt S; Polonsky B; Steinberg JS; Zareba W; Aktaş MK
JACC Clin Electrophysiol; 2023 Oct; 9(10):2122-2131. PubMed ID: 37656097
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
